Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 10,398 matching trials from the live ClinicalTrials.gov search.
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 3 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more
Conditions
Congenital Heart Disease
Interventions
Antithrombin III, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Day to 180 Days
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Prader-Willi Syndrome
Interventions
VYKAT XR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 22 more
Conditions
Dystrophinopathy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy
Interventions
L-arginine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 11 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gyrate Atrophy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cystic Fibrosis
Interventions
BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire
Diagnostic Test · Other · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more
Conditions
Turner Syndrome
Interventions
Humatrope
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 20 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 6 more
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Atopic Dermatitis, Eczema
Interventions
Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
0 Months to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Oakland, California • San Francisco, California • Baltimore, Maryland + 5 more
Conditions
Lung Diseases, Bronchopulmonary Dysplasia
Interventions
iNO, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 1 Year
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 11 more
Conditions
Solid Tumor, Unspecified, Adult
Interventions
RLY-1971
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Boston, Massachusetts + 1 more
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hereditary Angioedema
Interventions
KVD900, Placebo
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Tezacaftor/Ivacaftor matching placebo, Ivacaftor matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Conditions
Primary Ciliary Dyskinesia
Interventions
nNO testing
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Conditions
Laxity; Skin
Interventions
MCD
Device
Lead sponsor
Cytrellis Biosystems, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Sacramento, California • Miami, Florida • New York, New York + 2 more
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Hodgkin Lymphoma, Hodgkin Disease, Myelofibrosis, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Sickle Cell Disease, Mantle Cell Lymphoma
Interventions
Pre-biotic foods/drinks
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions
Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor, Campath
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland